['chronic hepatitis c']
['danoprevir', 'ritonavir', 'peginterferon alfa-2a', 'ribavirin (rbv)']

        Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Chronic HCV infection (≥ 6 months) ;

          -  Positive HCV antibody

          -  Serum HCV RNA of ≥ 1 × 104 IU/mL

          -  Hepatitis C virus GT1

          -  Never received prior-treatment for HCV with interferon, RBV, or other direct-acting or
             host-targeting antivirals for HCV

          -  The liver biopsy methods in the protocol (non-cirrhosis is defined as: Metavir score ˂
             4), or as determined by Fibroscan defined as: ˂ 14.6 kPa. Patients who have not
             obtained a liver biopsy or Fibroscan in the last 1 years will have a study related
             Fibroscan performed in order to confirm the diagnosis

          -  Others as specified in the detailed protocol

        Exclusion Criteria:

          -  Patients with Fibroscan detection value > 12.9 kPa, or histologic examination for
             liver cirrhosis patients

          -  Presence or history of non-hepatitis C chronic liver disease, including but not
             limited to, autoimmune hepatitis, α-1-antitrypsin deficiency, C282Y homozygous
             hemochromatosis, Wilson's disease, drug- or toxin-induced liver disease,
             alcohol-related liver disease, primary biliary cirrhosis, sclerosing cholangitis, and
             porphyria cutanea tarda causing liver pathology or requiring phlebotomy

          -  Patients with a history of liver cell cancer, screening before or screening suspected
             hepatocellular carcinoma (HCC) patients, or imaging studies found suspicious nodules,
             or AFP > 50 ng/mL

          -  Positive hepatitis A antibody，positive hepatitis B surface antigen，syphilis antibody
             or HIV antibody at screening

          -  Others as specified in the detailed protocol
      